Treatment Resistant Epilepsy. Epilepsy and recurrent seizures
Conditions
Interventions
Intervention 1: Intervention group: Patients diagnosed with frontal lobe epilepsy who are resistant to common drug therapies. These patients are randomly assigned to the intervention group according t
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Drug resistant frontal lobe epilepsy diagnosis (Insufficient or no response to two or more of anti epileptic agents)
Exclusion criteria
Exclusion criteria: Consumption of any derivative of marijuana or cannabis plant in recent month Pregnancy Any of the aforementioned medications in regimen: Clobazam, DesMethyl Clobazam, Eslicarbazepin, Topiramate, Zonisamide, Warfarin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in the seizure frequency in drug-resistant frontal lobe epilepsy following cannabidiol use. Timepoint: Before the intervention and after 14 weeks of taking the drug or placebo. Method of measurement: Based on the patient's history and counting the number of seizures per month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease in the severity of seizures after taking cannabidiol according to the Chalfont seizure severity scale. Timepoint: Before the intervention and after fourteen weeks of taking drug or placebo. Method of measurement: Based on the Chalfont seizure severity by scoring system.;Increase in quality of life in epilepsy following cannabidiol use. Timepoint: Before the intervention and after the fourteen weeks of taking medication or placebo. Method of measurement: Quality of Life in Epilepsy with 31 questions (QOLIE-31) questionnaire by scoring. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Reza Ebadi
Tehran University of Medical Sciences
Outcome results
None listed